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A Novel Biomarker of Coronary Atherosclerosis: Serum DKK1 
Concentration Correlates with Coronary Artery Calcification and 
Atherosclerotic Plaques
DKK1 modulates Wnt signaling, which is involved in the atherosclerosis. However, no data 
exist regarding the usefulness of measuring serum DKK1 concentration in predicting 
coronary atherosclerosis. A total of 270 consecutive patients (62.8 ± 11.2 yr; 70% male) 
were included. A contrast-enhanced 64-slice coronary MDCT was performed to identify 
the presence of atherosclerotic plaques. Agatston calcium scores (CS) were calculated to 
quantify the coronary artery calcification (CAC). DKK1 concentrations were measured by 
enzyme-linked immunosorbent assay. For each subsequent DKK1 quartile, there was a 
significant increase in CAC (P = 0.004) and the number of segments with coronary 
atherosclerosis (P < 0.001). In addition, DKK1 concentration was significantly higher in 
patients with atherosclerotic plaques, regardless of plaque composition (P = 0.01). 
Multivariate analysis identified DKK1 as an independent risk factor for the presence of 
coronary atherosclerotic plaque. The adjusted odds ratio for coronary atherosclerotic 
plaque was 4.88 (95% CI, 1.67 to 14.25) for highest versus lowest quartile of the DKK1 
levels. Furthermore, patients with DKK1 concentrations ≥ 68.6 pg/mL demonstrated 
coronary atherosclerotic plaques even when they had low CS. Serum DKK1 concentrations 
correlate with the coronary atherosclerosis and play an independent role in predicting the 
presence of coronary atherosclerosis. 
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Cardiovascular Disorders
INTRODUCTION
Coronary artery calcium is a marker of subclinical coronary ath-
erosclerotic disease and predicts coronary events. As a result, 
there has been considerable interest in the potential use of the 
coronary artery calcium score (CACS) using computed tomog-
raphy (CT) in models of risk prediction (1). Furthermore, with 
the advance of technology, contrast-enhanced CT angiography 
can identify both calcified and non-calcified coronary athero-
sclerotic plaques. The clinical usefulness of CACS and coronary 
CT angiography (CCTA) is well known and their use has recent-
ly increased (2, 3). However, the concern regarding radiation ex-
posure from CCTA has also increased (4). 
  A clinical risk score such as the Framingham risk score is help-
ful in identifying the high-risk group. However, more than half 
of the cardiac events develop in low-risk patients (5). Accord-
ingly, a more sophisticated method to stratify the cardiovascu-
lar risk needs to be developed. Finding new biomarkers that can 
identify and quantify the severity of coronary artery calcification 
(CAC) and atherosclerosis would be less expensive, avoid expo-
sure to radiation, and be more accessible than imaging based 
methods.
  The Wnt signaling pathways are involved in diverse develop-
mental and physiological processes, including cell differentia-
tion and tissue/organ morphogenesis (6). Recent evidence points 
to an important role of the Wnt signaling pathways in the regu-
lation of inflammation (7). In addition, Wnt pathway activation 
enhances monocyte adhesion and regulates trans-endothelial 
migration of monocytes. As a result, the Wnt signaling pathway 
is involved in the process of atherosclerosis (8). Moreover, the 
Wnt signaling pathway plays an important role in the vascular 
calcification (9, 10). 
  The canonical Wnt pathway is regulated by multiple families 
of secreted antagonists such as the soluble frizzled related re-
ceptors and dickkopf-1 (DKK1). DKK1 regulates Wnt signaling 
by binding to the Wnt co-receptor, LRP 5/6. Recently, enhanced Kim K-I, et al.  •  DKK1- A Novel Biomarker of Coronary Atherosclerosis
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DKK1 expression was observed within advanced carotid plaques, 
suggesting that a DKK1-driven inflammatory loop could be op-
erating within the atherosclerotic lesion (11). However, it has not 
been clearly demonstrated whether the serum concentration of 
DKK1 may be useful for predicting the extent of atherosclerosis 
or vascular calcification. 
  In this study, we aimed to evaluate the clinical significance of 
serum DKK1 concentration for predicting CAC and the presence 
of coronary atherosclerotic plaques. 
MATERIALS AND METHODS
Study population
We studied 270 consecutive subjects who visited Seoul National 
University Bundang Hospital complaining of chest pain from 
July 2006 through July 2008. The exclusion criteria were acute 
myocardial infarction, uncontrolled arrhythmia (ventricular 
tachycardia/fibrillation, atrial flutter/fibrillation, or atrioventric-
ular block greater than second degree), contrast allergy, and re-
nal dysfunction (serum creatinine > 2.0 mg/dL). Clinical infor-
mation was gathered by personal interview and a physical ex-
amination was performed by physicians. A biochemical evalu-
ation and full medical examination were also performed. 
  The estimated pretest probability for coronary artery disease 
was estimated using the Duke clinical score, which includes type 
of chest discomfort, age, gender, and traditional risk factors. Sub-
jects were categorized into a low (1% to 30%), intermediate (31% 
to 70%), or high (71% to 99%) risk group of having coronary ar-
tery disease (12). 
Coronary multidetector computed tomography (MDCT) 
and coronary artery calcium scoring 
All subjects were examined using the same CT unit and scanning 
protocols. All CT scans were performed using a 64-slice CCTA 
scanner (Brilliance 64, Philips Medical Systems, Best, The Neth-
erlands) with 64 × 0.625-mm section collimation, 420-ms rota-
tion time, 120-kV tube voltage, and 800-mA tube current under 
electrocardiographic-gated dose modulation. Before CCTA, all 
patients with a baseline heart rate > 70 beats/min received an 
intravenous esmolol of 10 to 30 mg (Jeil Pharm, Seoul, Korea). 
Nitroglycerin 0.6 mg was administered sublingually immediate-
ly before contrast injection (13). During CCTA acquisition, a bo-
lus of 80 mL iomeprol (Iomeron 400, Bracco, Milan, Italy) was in-
jected intravenously (4 mL/s) followed by a 50-mL saline chaser. 
  Coronary MDCT scans were analyzed independently by two 
experienced radiologists who were unaware of the clinical infor-
mation and used a three-dimensional workstation (Brilliance, 
Philips Medical Systems). Agatston calcium scores (CS) were 
calculated to quantify the extent of CAC (14). The presence of 
coronary atherosclerotic plaque was evaluated according to the 
modified American Heart Association classification (15). The 
contrast-enhanced portion of the coronary lumen was semi-
automatically traced at the maximal stenotic site and compared 
with the mean value of the proximal and distal reference sites. 
Structures that were > 1 mm
2 within and/or adjacent to the ves-
sel lumen were defined as plaques. Three groups of plaques were 
classified: lesions in which > 50% of the plaque area was occu-
pied by calcified tissue (density > 130 Hounsfield unit in native 
scans) were classified as calcified, lesions with < 50% calcium as 
mixed, and lesions without any calcium were classified as non-
calcified (16). 
Measurement of serum DKK1 concentration
DKK1 concentrations were measured by enzyme-linked immu-
nosorbent assay according to the manufacturer’s instructions 
(DuoSet ELISA development kit, R&D Systems Inc., Minneapo-
lis, MN, USA). 
Definitions
Hypertension was defined as blood pressure ≥ 140/90 mmHg 
or taking any antihypertensive medications. Diabetes mellitus 
was defined by a fasting blood glucose ≥ 126 mg/dL or a history 
of or treatment for hyperglycemia. Hypercholesterolemia was 
defined by a total cholesterol ≥ 200 mg/dL or treatment for hyper-
cholesterolemia. Ischemic heart disease was defined by a histo-
ry of angina, myocardial infarction, or previous treatment with 
coronary medications or intervention for heart disease. Smok-
ing status was classified into current smokers (smoked within 
the last month), ex-smokers (given up for more than one month), 
and non-smokers.
Statistical analysis
Statistical analyses were performed using SPSS (version 15.0, 
SPSS Inc., Chicago, IL, USA) or MedCalc (version 11.0, MedCalc 
software, Mariakerke, Belgium). Continuous variables are ex-
pressed as mean ± SD. Because serum DKK1 levels and CACS 
were not normally distributed, the values are also reported as 
median and interquartile range (IQR). Continuous variables 
were compared by either the unpaired Student’s t-test or analy-
sis of variance (ANOVA) followed by post-hoc comparison with 
the Scheffe test. Discrete variables are expressed as counts and 
percentages, and the chi-squared or Fisher’s exact test was used 
to compare proportions. Correlation analyses were performed 
using the Pearson and Spearman coefficients of correlation for 
parametric and nonparametric variables, respectively. Multiple 
logistic regressions were employed to assess the independent 
association of DKK1 concentration and CACS with the presence 
of coronary atherosclerotic plaque. Differences in the predicted 
value were estimated by comparing the area under the receiver-
operating characteristic curve (AUC), taking the correlation be-
tween the areas into account. We also calculated the c-statistic 
for models with conventional risk factors with and without CACS Kim K-I, et al.  •  DKK1- A Novel Biomarker of Coronary Atherosclerosis
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or DKK1. All statistical analyses were two-tailed, and P values < 
0.05 were considered statistically significant. 
Ethics statement 
All subjects provided informed consent and the study was ap-
proved by the institutional review board at Seoul National Uni-
versity Bundang Hospital (IRB number: B-0807/059-004).  
RESULTS
Baseline characteristics of study subjects
A total of 270 consecutive patients with chest pain were includ-
ed. The mean age was 62.8 ± 11.2 yr (range: 31-92 yr), and males 
comprised 70% of subjects. Of the 270 patients, 41 (15%) patients 
showed no evidence of coronary artery calcium. The mean value 
of CACS was 338.1 ± 518.7 (median 112.9, IQR 16.9-450.6). The 
mean serum concentration of DKK1 was 134.5 ± 127.2 pg/mL 
(median 99.8, IQR 61.6-158.5). Both CACS and DKK1 concen-
tration showed skewed distributions. Clinical and laboratory 
characteristics of the patients are presented in Table 1 accord-
ing to the quartile of DKK1 concentration. A significant increase 
in platelet count that correlated with increasing quartiles of DKK1 
concentration was identified. All other variables were not differ-
ent among the DKK1 quartiles.
Association between DKK1 concentration and coronary 
atherosclerosis 
The serum concentration of DKK1 was positively but weakly cor-
related with CACS (Spearman’s rho = 0.191, P = 0.002). CAC was 
significantly associated with the level of DKK1. The median (IQR) 
values of the CACS were 42.9 (0.0-224.8), 127.1 (22.2-612.3), 145.4 
(38.5-639.3), and 154.1 (44.8-444.5) in the lowest, second, third, 
and highest quartiles of DKK1 level (P = 0.004). Also, the distri-
bution of DKK1 and CACS quartiles were closely associated (P = 
0.021). Overall, any coronary atherosclerotic plaque (≥ 10% lu-
minal narrowing) was detected in 253 (94%) subjects, and the 
mean number of segments with coronary atherosclerotic plaques 
was 3.4 ± 1.8 per subjects. The number of segments with coro-
nary atherosclerosis was significantly higher in groups with high-
er DKK1 concentrations (P < 0.001) (Fig. 1A). In addition, DKK1 
concentration was significantly elevated according to the global 
coronary atherosclerotic burden (Fig. 1B).
  Significant coronary atherosclerotic stenosis (≥ 50% luminal 
narrowing) was identified in 212 (79%) subjects. Among these 
patients, 79 subjects had exclusively non-calcified plaques, 25 
subjects had exclusively calcified plaques, and 108 subjects had 
both and, thus, were classified as having mixed plaques. DKK1 
was significantly elevated in patients with coronary atheroscle-
rotic stenosis (median [IQR] with DKK1 concentrations of 63.2 
[52.7-102.8] pg/mL, 105.2 [64.4-169.1] pg/mL, and 108.5 [72.0-
Table 1. Comparison of clinical and laboratory characteristics according to the DKK1 quartile group
Parameters 1st quartile (n = 67) 2nd quartile (n = 68) 3rd quartile (n = 68) 4th quartile (n = 67) P value
Age (yr) 62.2 (11.0) 63.9 (12.0) 62.4 (10.5) 62.7 (11.3) 0.823
Male sex 41 (61.2%) 51 (75.0%) 48 (70.6%) 49 (73.1%) 0.307
HT 37 (55.2%) 45 (66.2%) 44 (64.7%) 39 (58.2%) 0.509
DM 26 (38.8%) 33 (48.5%) 27 (39.7%) 33 (49.3%) 0.465
Hypercholesterolemia 32 (47.8%) 38 (55.9%) 34 (50.0%) 32 (47.8%) 0.754
FHx of IHD 11 (16.4%) 11 (16.2%) 14 (20.6%) 13 (19.4%) 0.883
Smoking
   Ex-smoker
   Current smoker
 
24 (35.8%)
15 (22.4%)
 
23 (33.8%)
20 (29.4%)
 
26 (38.2%)
13 (19.1%)
 
20 (29.9%)
18 (26.9%)
0.818
BMI (kg/m
2) 24.6 (2.4) 25.5 (3.9) 25.1 (3.2) 24.6 (2.6) 0.234
WBC (× 10
3/µL) 6.8 (1.7) 7.2 (2.3) 6.8 (2.2) 7.1 (2.3) 0.534
Hemoglobin (g/dL) 13.7 (1.6) 13.8 (1.8) 13.9 (1.5) 13.7 (1.6) 0.838
Platelet (× 10
3/µL) 233.2 (52.2) 236.2 (62.9) 249.7 (68.9) 264.3 (69.3) 0.019
Fibrinogen (mg/dL) 338.8 (88.9) 340.3 (101.7) 346.8 (112.7) 340.0 (105.8) 0.632
Calcium (mg/dL) 8.6 (0.5) 8.6 (0.4) 8.5 (0.5) 8.7 (0.6) 0.108
Glucose (mg/dL) 119.3 (37.3) 135.0 (60.4) 129.6 (56.4) 128.5 (73.5) 0.520
Cholesterol (mg/dL) 180.5 (37.1) 180.8 (46.9) 175.4 (37.5) 178.9 (36.3) 0.852
TG (mg/dL) 154.4 (123.4) 137.9 (68.0) 153.1 (95.2) 137.0 (52.6) 0.564
HDL cholesterol (mg/dL) 43.3 (10.2) 44.6 (10.7) 46.9 (16.2) 43.6 (12.1) 0.376
BUN (mg/dL) 16.3 (5.7) 17.2 (5.3) 16.1 (5.1) 16.5 (6.3) 0.709
Creatinine (mg/dL) 1.0 (0.2) 1.1 (0.2) 1.0 (0.3) 1.0 (0.2) 0.108
HbA1C (%) 6.5 (1.8) 6.5 (1.1) 6.5 (1.3) 6.6 (1.3) 0.977
hsCRP (mg/L) 3.4 (4.2) 7.6 (16.1) 5.9 (13.4) 4.9 (11.5) 0.312
CACS 42.9 [0.0-224.8] 127.1 [22.2-612.3] 145.4 [38.5-639.3] 154.1 [44.8-444.5] 0.004
Data are presented as mean (SD) or number (%). CACS are presented as median [IQR]. DKK1, dickkopf-1; HT, hypertension; DM, diabetes mellitus; FHx of IHD, family history of 
ischemic heart disease; BMI, body mass index; WBC, white blood cell; TG, triglyceride; HDL, high density lipoprotein; BUN, blood urea nitrogen; HbA1C, hemoglobin A1C; hsCRP, 
high sensitivity C-reactive protein; CACS, coronary artery calcium score. Cutoff values for DKK1 quartiles were 61.6 pg/mL, 99.8 pg/mL, and 158.5 pg/mL.Kim K-I, et al.  •  DKK1- A Novel Biomarker of Coronary Atherosclerosis
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183.2] pg/mL in patients without plaque, with non-calcified 
plaque, and with mixed or calcified plaque, respectively) (P = 
0.01) (Fig. 2).
  The association between DKK1 concentration and coronary 
atherosclerotic stenosis was not different according to the pretest 
risk profile evaluated using the Duke clinical score. The frequen-
cy of coronary atherosclerotic stenosis was significantly increased 
according to the level of DKK1, both in the low to intermediate-
risk group (n = 72) and in the high-risk group (n = 198).
Comparison of CACS and DKK1 in predicting the presence 
of coronary atherosclerotic stenosis 
The levels of CACS were significantly higher in patients with cal-
cified or mixed plaque. However, the values were not different 
in patients with non-calcified plaque compared to patients with-
out plaques (Fig. 3).
  The AUC for the DKK1 concentration was 0.678 (95% CI: 0.619-
0.734), which was comparable to that of CACS (AUC 0.729, 95% 
CI: 0.672-0.782) (P = 0.260). The sensitivity and specificity of DKK1 
levels ≥ 68.6 pg/mL for the presence of coronary atherosclerotic 
plaques were 77% (71%-82%) and 55% (42%-68%), respectively. 
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Fig. 1. Association between DKK1 concentration and coronary atherosclerotic plaque. Number of coronary artery segments with any atherosclerotic plaque (≥ 10% luminal nar-
rowing) was evaluated in all the subjects, and 253 (94%) subjects showed more than one coronary atherosclerotic plaque. The number of segments with coronary atheroscle-
rosis was significantly increased with increasing DKK1 quartiles (A). In addition, DKK1 concentration was significantly elevated according to the number of coronary artery seg-
ments with any atherosclerotic plaque (B). An outliers (open circles) are defined as a score that is between 1.5 and 3 box lengths away from the upper edge of the box. An ex-
treme scores (asterisks) are defined as a score that is greater than 3 box lengths away from the upper edge of the box.
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Fig. 2. Comparison of DKK1 concentration according to the type of coronary athero-
sclerotic plaque. DKK1 was significantly elevated in patients with both calcium-con-
taining and non-calcified coronary atherosclerotic plaques compared to the patients 
without plaque. The central line represents distribution median, the boxes span from 
25th to 75th percentiles, and the error bars extend from 10th to 90th percentiles. An 
outliers (open circles) are defined as a score that is between 1.5 and 3 box lengths 
away from the upper edge of the box. An extreme scores (asterisks) are defined as a 
score that is greater than 3 box lengths away from the upper edge of the box.
C
o
r
o
n
a
r
y
 
a
r
t
e
r
y
 
c
a
l
c
i
u
m
 
s
c
o
r
e
  No plaque  Non-calcified plaque  Mixed or calcified plaque 
  (N = 58)  (N = 79)  (N = 133)
3,000
2,500
2,000
1,500
1,000
500
0
*
*
* *
*
* *
*
* * *
P < 0.001
P = 0.989
P < 0.001 by ANOVA
Fig. 3. CACS according to the coronary atherosclerotic plaque classification. CACS 
was only increased in patients with calcium-containing plaques compared to the pa-
tients without plaque. This difference showed the clinical advantage of DKK1 over 
CACS in predicting the presence of coronary atherosclerotic plaques without calcium 
deposits. Shown are box plots representing median and interquartile range (equiva-
lently the 25th and 75th percentiles). An outliers (open circles) are defined as a score 
that is between 1.5 and 3 box lengths away from the upper edge of the box. An ex-
treme scores (asterisks) are defined as a score that is greater than 3 box lengths 
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  For the prediction of coronary atherosclerotic plaques, im-
provement in discrimination compared with the model with con-
ventional risk factors was observed with inclusion of CACS (c-
statistic = 0.735) in the model and with DKK1 (c-statistic = 0.717). 
Addition of both CACS and DKK1 resulted in a statistically signif-
icant increase of the c-statistic compared with the model based 
on clinical risk factor or clinical risk factor plus either CACS or 
DKK1 (Fig. 4, Table 2). 
  In multivariate analysis, CACS and DKK1 concentrations re-
tained a strong association with the presence of coronary athero-
sclerotic plaque after adjustment for age, gender, and other vari-
ables (Table 3). Interestingly, the patients who had low CACS 
(Agatston CS < 154.1, cut-off value after the receiver-operating 
Table 2. C-Statistics: Incremental prognostic value of CACS and DKK1 concentration regarding the presence of coronary atherosclerotic plaques 
Model of plaques C-statistics P value* P value
† P value
‡
Model 1: Clinical risk indicator 0.634 (0.573-0.692)
Model 2: Clinical risk indicator + CACS  0.735 (0.678-0.787)    0.001
Model 3: Clinical risk indicator + DKK1 0.717 (0.659-0.770)    0.009   0.597
Model 4: Clinical risk indicator + CACS + DKK1 0.773 (0.719-0.822) < 0.001 0.05 0.01
Clinical risk indicator includes age, body mass index, hypertension, diabetes, and hypercholesterolemia. *P value comparing with model 1; 
†P value comparing with model 2; 
‡P 
value comparing with model 3. DKK1, dickkopf-1; CACS, coronary artery calcium score.
Table 3. Unadjusted and adjusted OR and 95% confidence intervals derived from   
logistic regression analysis for the association between CACS and DKK1 concentra-
tion with the presence of coronary atherosclerotic plaques 
Variables Odds ratio 95% CI P value
Model 1
   CACS, Q1*
   CACS, Q2
   CACS, Q3
   CACS, Q4
   DKK-1, Q1*
   DKK-1, Q2
   DKK-1, Q3
   DKK-1, Q4
 
-
1.58
3.84
9.04
-
1.40
2.73
4.98
 
-
0.74-3.38
1.59-9.25
2.87-28.52
-
0.64-3.10
1.13-6.61
1.82-13.64
 
-
0.243
0.003
< 0.001
-
0.404
0.026
0.002
Model 2
   CACS, Q1*
   CACS, Q2
   CACS, Q3
   CACS, Q4
   DKK-1, Q1*
   DKK-1, Q2
   DKK-1, Q3
   DKK-1, Q4
-
1.50
3.69
9.06
-
1.29
2.66
4.56
-
0.66-3.42
1.44-9.44
2.66-30.91
-
0.58-2.88
1.09-6.50
1.65-12.60
-
0.330
0.007
< 0.001
-
0.539
0.032
0.003
Model 3
   CACS, Q1*
   CACS, Q2
   CACS, Q3
   CACS, Q4
   DKK-1, Q1*
   DKK-1, Q2
   DKK-1, Q3
   DKK-1, Q4
 
-
1.55
3.39
7.21
-
1.20
2.36
4.88
 
-
0.65-3.71
1.28-9.00
2.01-25.82
-
0.51-2.82
0.94-5.97
1.67-14.25
 
-
0.321
0.014
0.002
-
0.672
0.068
0.004
The dependent variable was the presence of coronary atherosclerotic plaque causing 
more than 50% stenosis. *The first quartile (Q1) was used as the reference value. Cut-
off values were 16.9, 112.9, and 450.6 for CACS quartiles and 61.6 pg/mL, 99.8 pg/ 
mL, and 158.5 pg/mL for DKK1 quartiles. Model 1, unadjusted; Model 2, age and gen-
der adjusted; Model 3, age, gender, hypertension, diabetes mellitus, hypercholesterol-
emia, smoking, calcium, creatinine, fibrinogen, hsCRP, and platelet count adjusted. 
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Fig. 4. Role of DKK1 in predicting the presence of coronary atherosclerotic plaque. 
The receiver operating characteristic curves illustrate clinical risk indicator including 
age, body mass index, hypertension, diabetes, and dyslipidemia alone or plus CACS 
and/or DKK1 concentration. Areas under the curves are 0.634 for clinical risk indica-
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CACS or DKK1, and CACS & DKK1 are significantly greater than that of the clinical risk 
indicator alone. 
Fig. 5. Complementary role of DKK1 and CACS in identifying coronary atherosclerotic 
plaque. Patients who had low CACS (Agatston CS < 154.1) but high DKK1 concen-
tration (DKK1 ≥ 68.6 pg/mL) show a similar probability of having coronary athero-
sclerotic plaque as patients with high CACS.
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characteristic curve analysis) but DKK1 ≥ 68.6 pg/mL showed a 
similar probability of having coronary atherosclerotic plaque as 
patients with high CACS (Agatston CS ≥ 154.1) (Fig. 5).
DISCUSSION
In this study, we demonstrated that DKK1 concentration signif-
icantly correlated with CAC and the presence of coronary ath-
erosclerotic plaque. Furthermore, in patients with a low CACS, 
DKK1 concentration could be useful to identify the presence of 
coronary plaque. 
  CACS alone can rank the risk of coronary heart disease inde-
pendently of the clinical risk profile and shows good correlation 
with calcified atherosclerotic plaque. However, the efficacy of 
CACS for predicting non-calcified coronary plaques has shown 
limited potential (17). Moreover, a zero CACS result does not ex-
clude significant coronary artery stenosis or the need for coro-
nary revascularization (18). 
  Contrary to CACS, DKK1 can identify non-calcified as well as 
calcium-containing plaques without radiation exposure. In ad-
dition, DKK1 provides incremental information regarding the 
prediction of coronary atherosclerotic plaque beyond tradition-
al risk factors. All of these results merit further investigation of 
DKK1 measurement in various clinical situations for identifying 
coronary atherosclerosis.
  The hallmark of the DKK family is its ability to modulate Wnt 
signaling. The founding member of the family, DKK1, was dis-
covered by its ability to block Wnt signaling (19, 20). The Wnt sig-
naling pathway is involved in inflammation and atherosclero-
sis. In addition, the role of Wnt signaling during vascular calcifi-
cation has been established. Aicher et al. have shown that DKK1 
induces the osteoclast differentiation factor RANKL, which has 
an important role in vascular calcification (21, 22). Moreover, 
Ueland et al. (11) have demonstrated that DKK1 expression is 
enhanced in advanced carotid plaques and that DKK1 is a novel 
mediator in platelet-mediated endothelial cell activation, which 
could occur within the atherosclerotic lesions. All of these find-
ings suggest that DKK1 may modulate vascular calcification and 
atherosclerosis. However, until now there was no concrete evi-
dence showing the clinical implication of measuring serum DKK1 
concentrations in the patients. 
  In this study, we observed a positive correlation between the 
serum concentration of DKK1 and CAC. Furthermore, the DKK1 
concentration was significantly increased in patients with CAC 
and atherosclerotic plaques. Interestingly, DKK1 concentration 
was significantly different between patients without plaque and 
with non-calcified plaque; however, CACS showed no difference 
between these patients. 
  With the advance of technological improvement, CCTA could 
characterize coronary atherosclerotic plaques. New technologies 
enable us to identify non-calcified coronary plaques, but there 
are concerns about the associated radiation exposure. Accord-
ingly, a new method to identify both non-calcified and calcium-
containing plaques needs to be developed. From this point of 
view, the measurement of DKK1 concentration in addition to 
CACS would be beneficial for the prediction of coronary artery 
disease in patients with chest pain. However, it is not obvious 
whether this result could also be applied to other populations, 
such as asymptomatic individuals or other ethnic backgrounds. 
Furthermore, it is not clear whether DKK1 is also useful to pre-
dict systemic atherosclerosis other than coronary atherosclero-
sis. Accordingly, the association between DKK1 concentration 
and systemic atherosclerosis in carotid, aorta, and peripheral 
vessels need to be evaluated. 
  We observed a significant increase in platelet count that cor-
related with increasing quartiles of DKK1 concentration. Previ-
ous report demonstrated that DKK1 is a mediator in platelet-de-
pendent endothelial activation (11). However, the association 
between DKK1 and coronary atherosclerotic plaques remained 
significant after adjustment for platelet count in multivariate 
analysis.
  In conclusion, serum DKK1 concentrations correlate with the 
presence of CAC and play a role in predicting the presence of 
coronary atherosclerotic plaques. The measurement of DKK1 
merits further investigation as a simple test for identifying coro-
nary atherosclerosis without the risk of radiation exposure. 
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A Novel Biomarker of Coronary Atherosclerosis: Serum DKK1 Concentration 
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Here, we show that DKK1 concentration is significantly associated with coronary artery calcification and coronary atherosclerotic 
plaques. Furthermore, in patients with low calcium scores, DKK1 concentration is valuable in differentiating the presence of 
coronary plaques. Accordingly, measuring the serum DKK1 concentration is clinically useful for identifying coronary 
atherosclerosis.